Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.78 |
| ▸ | MAPT | P10636 | 3/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | TSHR | P16473 | 2/20 | 0.78 |
| ▸ | BLM | P54132 | 2/20 | 0.78 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | MPO | P05164 | 1/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | HTR7 | P34969 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Tryptophan SCHEMBL152717 | 1.00 | KMT2A (0.78) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL27561249 | 1.00 | KMT2A (0.78) | KMT2AKDM4EMAPTLMNATSHR | |
| D-Tryptophan SCHEMBL10359011 | 0.99 | KMT2A (0.80) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL243574 | 0.99 | KMT2A (0.80) | KMT2AKDM4EMAPTLMNATSHR | |
| D-Tryptophan SCHEMBL10359012 | 0.99 | KMT2A (0.80) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL15168746 | 0.99 | KMT2A (0.80) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL243573 | 0.99 | KMT2A (0.80) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL6032938 | 0.99 | KMT2A (0.80) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL27153674 | 0.99 | KMT2A (0.80) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL4224667 | 0.95 | KMT2A (0.71) | KMT2AKDM4EMAPTLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 721 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772290-B2 | Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same | Oscotech Inc. (KR) | 2014-07-08 | — | — | US | claimed |
| EP-2565180-A2 | ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Oscotec Inc. (KR) | 2013-03-06 | — | — | EP | claimed |
| US-20120149707-A1 | ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | OSCOTEC INC. (KR) | 2012-06-14 | — | — | US | claimed |
| WO-2024074847-A1 | COMPOSITIONS FOR DETECTING BIOLOGICAL AGENTS | PATH SPRAY LTD (GB) | 2024-04-11 | — | — | WO | disclosed |
| EP-3565837-B1 | COMBINED TREATMENT WITH NETRIN-1 INTERFERING DRUG AND IMMUNE CHECKPOINT INHIBITORS DRUGS | NETRIS PHARMA (FR) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024069191-A1 | CLOSTRIDIAL NEUROTOXIN FOR USE IN A TREATMENT OF BLADDER PAIN SYNDROME | IPSEN BIOPHARM LIMITED (GB) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024069176-A1 | CLOSTRIDIAL NEUROTOXINS COMPRISING AN ACTIVATING EXOGENOUS PROTEASE CLEAVAGE SITE | IPSEN BIOPHARM LIMITED (GB) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024069175-A1 | CLOSTRIDIAL NEUROTOXINS COMPRISING AN ACTIVATING ENDOSOMAL PROTEASE CLEAVAGE SITE | IPSEN BIOPHARM LIMITED (GB) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024057031-A1 | CELL-FREE CLOSTRIDIAL NEUROTOXIN ASSAYS | IPSEN BIOPHARM LIMITED (GB) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024049682-A2 | PROTEINS FOR CROSS-LINKING BIOPOLYMERS | ZYMERGEN INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| CN-110291105-B | Combination therapy of guide-1 interfering drugs and immune checkpoint inhibitor drugs | 奈特里斯药物公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-1996017067-A1 | METHOD FOR SECRETING THROMBOPOIETIN POLYPEPTIDES | ZYMOGENETICS, INC. (US) | 1996-06-06 | — | — | WO | disclosed |
| WO-1996017062-A1 | LOW MOLECULAR WEIGHT THROMBOPOIETIN | ZYMOGENETICS, INC. (US) | 1996-06-06 | — | — | WO | disclosed |
| WO-1995021626-A1 | METHODS FOR STIMULATING ERYTHROPOIESIS USING THROMBOPOIETIN | UNIVERSITY OF WASHINGTON (US) | 1995-08-17 | — | — | WO | disclosed |
| WO-1995021920-A1 | HEMATOPOIETIC PROTEIN AND MATERIALS AND METHODS FOR MAKING IT | ZYMOGENETICS, INC. (US) | 1995-08-17 | — | — | WO | disclosed |
| EP-0463154-A1 | POLYPEPTIDE AND AMINO ACID BASED COMPOSITION | MEDGENIX GROUP, S.A. (BE) | 1992-01-02 | — | — | EP | disclosed |
| WO-1991010441-A1 | POLYPEPTIDE AND AMINO ACID BASED COMPOSITION | MEDGENIX GROUP S.A. (BE) | 1991-07-25 | — | — | WO | disclosed |
| WO-1990000894-A1 | CYTO-PHOTO-PROTECTOR AGENT BASED ON NUCLEIC ACIDS AND/OR THEIR DERIVATIVES | LABORATOIRES SEROBIOLOGIQUES (FR) | 1990-02-08 | — | — | WO | disclosed |
| US-4650661-A | OF RENIN, OLIGOPEPTIDE HYPOTENSIVES | AKTIEBOLAGET HASSLE | 1987-03-17 | — | — | US | disclosed |
| US-4609643-A | OLIGOPEPTIDE ANALOG, HYPOTENSIVE | AKTIEBOLAGET HASSLE (SE) | 1986-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149707-A1 | ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | HIF1A, HIF1AN, EGLN3 | KMT2A 2186/4885KDM4E 533/4885MAPT 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.